Target Therapy Combined ~(188)re with Pingyangmycin on Prostate Cancer Cells in Vitro

Xīn Gào,Sun Yat-sen

2008-01-01

Abstract:[Objective] To investigate the efficacy of monoclonal antibody 7E11C5.3-targeted therapy combined 188Re with pingyangmycin for the treatment of human prostate cancer cell line LNCaP in vitro. [Methods] Linking between 7E11C5.3 and PYM was mediated by dextran T 40. Immunoreactivity of 7E11C5.3 was determined by indirect ELISA.Bacteria inhibitory activity of the conjugate was determined by TTC assay. 188Re-7E11C5.3 was prepared by direct 2-mercaptoethanol reduction method. Labeling efficiency and radiochemical purity was measured by paper chromatography. Immunoreactive fraction was determined by linear extrapolation. Cytotoxicity to LNCaP cells was determined by MTT assay. [Results] The molar ratio of 7E11C5.3:PYM was l:54 in 7E11C5.3-PYM conjugate. The immunoreactivity of 7E11C5.3 decreased by approximately 10%-20% after conjugation. The bacteriostatic activity of PYM in the conjugate was 25% as much as that of free PYM. The labeling yield of 188Re-7E11C5.3 was 93.16% ± 2.18%, the radiochemical purity was 95.62% ± 0.48%, and the immunoactive fraction was 74.86% ± 1.86%. The inhibitory effect of 7E11C5.3-PYM and 188Re-7E11C5.3 on cultured LNCaP cells was significantly higher than that of free PYM and 188ReO4- respectively. When separately used, the 50% inhibitory doses (IC50) of 7E11C5.3-PYM and 188Re-7E11C5.3 were (10.17 ± 2.06) ?μg/mL and (23.38 ± 3.73)×104 Bq/mL respectively. When combined used, the IC50s of 7E11C5.3-PYM and 188Re-7E11C5.3 were (1.83±0.20) ?μg/mL and (6.82±0.73)×104 Bq/mL respectively. [Conclusions] The combined use of 7E11C5.3-PYM and 188Re-7E11C5.3 displayed higher inhibitory effect on prostate cancer cells than their separate use.